Practical aspects of apixaban use in clinical practice: continuing the theme
Currently there are no generally accepted guidelines for the use of apixaban together with CYP3A4 and/or P-glycoprotein (P-gp) inhibitors. Analysis of clinical and pharmacological studies suggests that apixaban dose should be reduced to 2.5 mg twice daily when co-administered with a strong CYP3A4 an...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Столичная издательская компания
2015-11-01
|
| Series: | Рациональная фармакотерапия в кардиологии |
| Subjects: | |
| Online Access: | https://www.rpcardio.online/jour/article/view/330 |
| _version_ | 1797232423579156480 |
|---|---|
| author | S. N. Bel'diev |
| author_facet | S. N. Bel'diev |
| author_sort | S. N. Bel'diev |
| collection | DOAJ |
| description | Currently there are no generally accepted guidelines for the use of apixaban together with CYP3A4 and/or P-glycoprotein (P-gp) inhibitors. Analysis of clinical and pharmacological studies suggests that apixaban dose should be reduced to 2.5 mg twice daily when co-administered with a strong CYP3A4 and P-gp inhibitors, such as azole antimycotics, HIV protease inhibitors and clarithromycin. However, it is preferred to avoid apixaban combination with strong CYP3A4 and P-gp inhibitors in patients with a creatinine clearance (CrCl) <30 mL/min. According to preliminary calculations, apixaban dose should also be adjusted in patients with CrCl <70-80 ml/min, receiving less potent inhibitors of CYP3A4 and/or P-gp, such as diltiazem, naproxen, verapamil, amiodarone and quinidine. |
| first_indexed | 2024-03-08T14:05:35Z |
| format | Article |
| id | doaj.art-05ae2929ff564c7f9608d65b28d5d72e |
| institution | Directory Open Access Journal |
| issn | 1819-6446 2225-3653 |
| language | English |
| last_indexed | 2024-04-24T16:00:02Z |
| publishDate | 2015-11-01 |
| publisher | Столичная издательская компания |
| record_format | Article |
| series | Рациональная фармакотерапия в кардиологии |
| spelling | doaj.art-05ae2929ff564c7f9608d65b28d5d72e2024-04-01T07:43:24ZengСтоличная издательская компанияРациональная фармакотерапия в кардиологии1819-64462225-36532015-11-0111554354710.20996/1819-6446-2015-11-5-543-547330Practical aspects of apixaban use in clinical practice: continuing the themeS. N. Bel'diev0Tver State Medical University. Sovetskaja ul. 4, Tver, 170100 RussiaCurrently there are no generally accepted guidelines for the use of apixaban together with CYP3A4 and/or P-glycoprotein (P-gp) inhibitors. Analysis of clinical and pharmacological studies suggests that apixaban dose should be reduced to 2.5 mg twice daily when co-administered with a strong CYP3A4 and P-gp inhibitors, such as azole antimycotics, HIV protease inhibitors and clarithromycin. However, it is preferred to avoid apixaban combination with strong CYP3A4 and P-gp inhibitors in patients with a creatinine clearance (CrCl) <30 mL/min. According to preliminary calculations, apixaban dose should also be adjusted in patients with CrCl <70-80 ml/min, receiving less potent inhibitors of CYP3A4 and/or P-gp, such as diltiazem, naproxen, verapamil, amiodarone and quinidine.https://www.rpcardio.online/jour/article/view/330apixabanclinical pharmacologydrug-drug interactions |
| spellingShingle | S. N. Bel'diev Practical aspects of apixaban use in clinical practice: continuing the theme Рациональная фармакотерапия в кардиологии apixaban clinical pharmacology drug-drug interactions |
| title | Practical aspects of apixaban use in clinical practice: continuing the theme |
| title_full | Practical aspects of apixaban use in clinical practice: continuing the theme |
| title_fullStr | Practical aspects of apixaban use in clinical practice: continuing the theme |
| title_full_unstemmed | Practical aspects of apixaban use in clinical practice: continuing the theme |
| title_short | Practical aspects of apixaban use in clinical practice: continuing the theme |
| title_sort | practical aspects of apixaban use in clinical practice continuing the theme |
| topic | apixaban clinical pharmacology drug-drug interactions |
| url | https://www.rpcardio.online/jour/article/view/330 |
| work_keys_str_mv | AT snbeldiev practicalaspectsofapixabanuseinclinicalpracticecontinuingthetheme |